Lawmakers press DSS on Medicaid coverage for GLP‑1 obesity drugs as costs and federal policy shift debate

Connecticut lawmakers pressed the Department of Social Services on March 6 over whether Husky members will get access to FDA‑approved GLP‑1 weight‑loss medications after the legislature required coverage in 2023.

Several state senators and representatives challenged Commissioner Andrea Barton Reeves about delays and apparent inconsistencies in implementing Public Act 23‑94, which directs Medicaid to cover FDA approved drugs for obesity (for people with BMI thresholds set in statute). Lawmakers and patient advocates described cases where Medicaid beneficiaries had trouble obtaining refills or were denied coverage unless they met diabetes or other comorbidity codes.

Commissioner Reeves told the Human Services Committee that while Medicaid already covers two FDA‑approved GLP‑1s for type 2 diabetes, there are no generic GLP‑1s approved for obesity at this time and that federal guidance and budget realities complicate expanding coverage. She repeatedly urged formation of an advisory committee to study cost‑effective access approaches and recommended learning from other states and the state employee health plan. Reeves also described conversations with the Office of the State Comptroller and expressed concern about long‑term sustainability and the governor’s budget, which does not currently include the resources DSS would need for broad coverage.

Lawmakers pushed back, noting the 2023 statute mandates coverage and citing constituent reports of interrupted refills. Senator Eric Lesser and Representative Quentin Smith pressed DSS to explain why a Husky bulletin and a state plan amendment process appear inconsistent with beneficiaries’ experiences. Commissioner Reeves acknowledged recent federal changes (noting a new HHS position on health‑related social needs waivers) and said staffing and budget constraints would affect timing. She said a focused advisory committee could identify mechanisms such as procurement, therapeutic interchange, or state buying strategies to improve affordability.

Medical and consumer advocates told the committee that limiting coverage to older, cheaper drugs such as orlistat or phentermine would be clinically inadequate because GLP‑1 class drugs now drive most of the obesity‑treatment advances. The Connecticut affiliate of national clinical groups asked for coverage consistent with the 2023 law and urged DSS to avoid a double standard that would offer newer drugs for some conditions (for example, diabetes) but not for obesity. Several providers and witnesses said coverage is vital to address racial and economic health disparities — Black and Hispanic people have higher obesity prevalence and are overrepresented in Medicaid rolls.

The committee asked DSS to return with clearer options and cost estimates and encouraged fresh collaboration with CMS and the Office of the Comptroller. Advocates urged the agency to implement the statute without further delay or technical caveats that leave patients in coverage limbo.

Ending: The panel did not vote. Members said they expect follow up from DSS and urged the department to brief the legislature on an explicit timeline and financial analysis for implementing coverage consistent with the 2023 law.